Table 6. Disease-free survival Cohort .... | American Society of Hematology

Table 6.

Disease-free survival

Cohort	Any cGVHD		Lim, ext		Mild, mod, sev		Low, int, high
Cohort	RR^6-150	95% CI	RR^6-150	95% CI	RR^6-150	95% CI	RR^6-150	95% CI
IBMTR-1	1.0	(0.8-1.2)	0.6^6-154	(0.4-0.8)	0.5^6-155	(0.4-0.7)	0.5^6-154	(0.4-0.7)
			1.3	(1.0-1.6)	1.0^6-154	(0.7-1.3)	1.1^6-154	(0.8-1.4)
					2.9	(2.2-3.9)	2.0	(1.5-2.7)
IBMTR-2	1.3^6-151	(1.0-1.7)	0.9^6-155	(0.6-1.3)	0.8	(0.5-1.1)	0.8^6-154	(0.6-1.2)
			1.8	(1.3-2.4)	1.1^6-154	(0.8-1.7)	2.0	(1.4-3.0)
					4.5	(3.1-6.5)	2.2	(1.5-3.3)
NMDP	1.5^6-152	(1.1-1.9)	1.2	(0.8-1.7)	N/A		0.7	(0.4-1.2)
			1.5	(1.2-2.0)			1.2^6-153	(0.8-1.7)
							2.0	(1.3-3.1)

Cohort	Any cGVHD		Lim, ext		Mild, mod, sev		Low, int, high
Cohort	RR^6-150	95% CI	RR^6-150	95% CI	RR^6-150	95% CI	RR^6-150	95% CI
IBMTR-1	1.0	(0.8-1.2)	0.6^6-154	(0.4-0.8)	0.5^6-155	(0.4-0.7)	0.5^6-154	(0.4-0.7)
			1.3	(1.0-1.6)	1.0^6-154	(0.7-1.3)	1.1^6-154	(0.8-1.4)
					2.9	(2.2-3.9)	2.0	(1.5-2.7)
IBMTR-2	1.3^6-151	(1.0-1.7)	0.9^6-155	(0.6-1.3)	0.8	(0.5-1.1)	0.8^6-154	(0.6-1.2)
			1.8	(1.3-2.4)	1.1^6-154	(0.8-1.7)	2.0	(1.4-3.0)
					4.5	(3.1-6.5)	2.2	(1.5-3.3)
NMDP	1.5^6-152	(1.1-1.9)	1.2	(0.8-1.7)	N/A		0.7	(0.4-1.2)
			1.5	(1.2-2.0)			1.2^6-153	(0.8-1.7)
							2.0	(1.3-3.1)

For abbreviations see Table 3.

F6-150

Adjusted for disease type (acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia), disease stage (early, intermediate, advanced), age (years), patient-donor sex matching, and presence of prior acute GVHD (yes, no).

F6-151

P ≤ .01 compared with no cGVHD.

F6-152

P ≤ .001 compared with no cGVHD.

F6-153

P ≤ .01 compared with the next most severe category.

F6-155

P ≤ .001 compared with the next most severe category.

F6-154

P ≤ .0001 compared with the next most severe category.

View Large

This Feature Is Available To Subscribers Only